Industry: Healthcare
Published Date: January-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP33296
The market size of the High Potency Active Pharmaceutical Ingredients was around US$ 23.3 Bn in 2023, and now it is expected to grow with a CAGR of 10.9% from 2024 to 2033.
The use of HPAPIs has increased in recent years as a result of the high prevalence of cancer cases around the world, fuelling market growth. The High Potency Active Pharmaceutical Ingredients Market, accounted for an absolute dollar opportunity of nearly US$ 41.8 Bn from 2024 to 2033.
|
Attribute |
Details |
|
Global Market Size (2024) |
US$ 25.8 Bn |
|
Global Market Size (2033) |
US$ 65.1 Bn |
|
Market CAGR (2024 to 2033) |
10.9% |
|
Historical Market CAGR (2019 to 2023) |
8.9% |
|
Key Companies Profiled |
|
As per the High Potency Active Pharmaceutical Ingredients industry research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2018 to 2023, the market value of the High Potency Active Pharmaceutical Ingredients increased at around 8.9% CAGR. Growing with an absolute dollar opportunity of US$ 41.8 Billion, the market is expected to reach a valuation of US$ 65.1 Billion by 2033.
In this technology-driven market, patent expiration and the subsequent launch of generic versions offer pharmaceutical businesses a lucrative opportunity to extend their product portfolio and enter attractive market sectors.
In Europe, a number of biosimilars have been approved, while the FDA in the United States has only approved one so far. Increased research and development efforts, as well as continuous attempts to replicate branded biological medications, would pave the way for the launch of cost-effective treatment options.
Several successful medications are projected to lose patent protection in the near future, presenting significant prospects for biosimilars., Remicade (Infliximab), Herceptin (Trastuzumab), Avastin (Bevacizumab), Erbitux (Cetuximab), Synagis (Palivizumab), Humira (Adalimumab), and Rituxan (Rituximab) are few of the key medications that will soon lose their patent protection.
Several countries have enacted strict regulatory rules for the production of pharmaceutical ingredients since the pharmaceutical sector continues to grow at a rapid pace. These criteria have been imposed on firms in order to govern their manufacturing quality, hence improving the end product's therapeutic effectiveness. Rising in-house API manufacturing overhead expenses exacerbate this, which has caused pharmaceutical companies to shift their focus away from in-house production. As a result, several businesses have decided to outsource their API production.
Asia Pacific is one of the regions that has seen enormous expansion in manufacturing, owing to which firms in western countries cite Asia Pacific as a relatively low-cost alternative for outsourcing production.
Various manufacturers currently have a strong presence in China and India, prompting biopharmaceutical companies to seek out contract development and manufacturing firms (CDMOs). For example, AGC Biologics, a worldwide biopharmaceutical CDMO, announced a collaboration with Ono Pharmaceutical Co., Ltd. in August 2020 for the development of new and innovative biopharmaceuticals in the clinical development stage. As a result, these companies have the technical know-how and capacities to manufacture APIs on a large scale, which is expected to boost the market throughout the forecast period.
Which region is expected to showcase a significant opportunity for High Potency Active Pharmaceutical Ingredients Market?
The market in North America is expected to be the most lucrative. The market in the region is expected to surpass a valuation of US$ 25 Billion by 2033. Chronic diseases are becoming more common in North America, and government programs to create novel medications are becoming more common.
In addition, the increased adoption of biological pharmaceuticals among patients for the treatment of a variety of chronic diseases is fuelling demand for biological APIs in North America. According to the Alzheimer's Association, roughly 6.2 Million people in the United States over the age of 65 have Alzheimer's dementia, with the number expected to rise to 12.7 Million by 2050. Thus owing to the rise in the incidence of chronic illnesses, the market in the region has been experiencing significant growth.
The market in Asia Pacific is expected to surge on account of the growing number of contract manufacturing organizations and pharmaceutical businesses in countries like China and India.
U.S. High Potency Active Pharmaceutical Ingredients Market Analysis
The market in the U.S. is expected to reach a valuation of US$ 22.8 Billion by 2033. Growing with a CAGR of 10.6% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 14.5 Billion.
U.K High Potency API Market Analysis
The market in the U.K. is expected to reach a valuation of US$ 3.4 Billion by 2033. Growing with a CAGR of 13.3% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 2.4 Million.
China High Potency API Market Analysis
The market in China is expected to reach a valuation of US$ 6.6 Billion by 2033. Growing with a CAGR of 11.7% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 4.4 Billion.
Due to reasons such as cheaper labor costs and a plentiful supply of raw materials for manufacture, China has become a prevalent location for outsourcing active ingredient manufacturing. Furthermore, several Chinese manufacturers are enticed by the region's favorable regulatory rules to develop their production facilities, boosting the market growth in the country.
Japan High Potency API Market Analysis
In Japan, the market is expected to grow at a CAGR of 14.2% from 2023 to 2033, reaching around US$ 2.8 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 2 Billion during the forecast period.
Why is the high potency active pharmaceutical ingredients market growing in response to rising demand for oncology drugs?
Because of the increased need for oncology treatments, the global market for HPAPIs is expected to grow dramatically. HPAPIs are pharmacologically active compounds with a high level of efficacy. They work with an accurate mechanism of action and prove to be effective even at modest daily therapeutic doses. HPAPIs have the ability to target specific cancer cells and are employed in high-efficiency therapeutic formulations such as oncology treatments.
HPAPIs have several applications in cancer target therapy because of their target release features. The cancer incidences has been rising dramatically globally. According to the World Health Organization, 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million persons living with cancer (within 5 years of diagnosis) were reported globally in 2012.
According to the American Cancer Society, over 15.5 million Americans were diagnosed with cancer in January 2016, with over 1,688,780 additional cases predicted to be diagnosed in 2018, bringing the total to 20 million within 17 years, according to the report.
The increase in cancer diagnoses has a significant impact on medicine and therapy sales around the world. As a result, the worldwide HPAPI market is expected to be flooded with opportunities as the demand for oncology medications grows. According to a report published in Nature Reviews, the pharmaceutical industry's 20 top-selling cancer medications produce yearly sales of more than US$ 50 billion worldwide, with Roche's Rituxan, Avastin, and Herceptin earning US$ 21 billion.
What are the growth prospects in the market for the biological segment?
Due to an increase in demand for biopharmaceuticals and an increasing number of biologics innovations to address the significant unmet medical requirements for various illnesses, the biological segment is expected to grow at a fast pace between 2023 and 2033. Furthermore, the biological API industry is likely to be a high-profit segment, attracting significant pharmaceutical and biopharmaceutical firms.
The rising number of FDA approvals for biological pharmaceuticals, such as blood components, recombinant proteins, and vaccines are expected to propel the biological segment forward at a rapid pace over the projection period. Richcore LifeSciences, an Indian biotechnology business, for example, announced the establishment of a new recombinant protein manufacturing plant in July 2020. The facility will have a 180,000-liter fermentation capacity for producing recombinant protein for pharmaceuticals, cell culture, and food industry applications.
The key players in the global High Potency Active Pharmaceutical Ingredients Market are BASF SE, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Carbogen Amcis AG, and Pfizer Inc.
By Product Type
By Manufacturer Type
By Drug Type
By Application
By Region
To know more about delivery timeline for this report Contact Sales
The global High Potency Active Pharmaceutical Ingredients market size was estimated at US$ 21.2 Billion in 2022 and is expected to grow further to US$ 23.3 Billion in 2023.
The market value is projected to increase at a CAGR of around 10.9% from 2023 to 2033.
The market value increased at a CAGR of around 8.9% from 2018 to 2022.
The use of HPAPIs has increased in recent years as a result of the high prevalence of cancer cases around the world, fuelling the growth of the High Potency Active Pharmaceutical Ingredient (HPAPI) Market.
Top 5 countries driving demand for the High Potency Active Pharmaceutical Ingredients Market are the United States, China, Japan, U.K. and South Korea.
United States accounted for over 39% of global High Potency Active Pharmaceutical Ingredients Market demand in 2022.
The UK market for High Potency Active Pharmaceutical Ingredients Market is projected to expand at a CAGR of around 13.3% from 2023 to 2033.
